uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026)
uniQure (QURE) recorded quarterly Net Income towards Common Stockholders of -$53.5 million in Q1 2026, down 187.14% quarter-over-quarter from -$18.6 million in Q4 2025, and down 22.68% on a YoY basis from -$69.2 million in Q1 2025.
uniQure (QURE) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
uniQure's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$53.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 22.68% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$189.3 million (up 12.99% YoY), while the FY2025 annual figure was -$199.0 million, up 16.94% from the prior year.
- Net Income towards Common Stockholders was -$53.5 million for Q1 2026 at uniQure, down from -$18.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $6.8 million in Q4 2022 to a low of -$89.6 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$53.4 million across 5 years, with a median of -$53.5 million in 2026.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 1175.45% in 2023, then surged 74.55% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $6.8 million in 2022, then tumbled by 1175.45% to -$73.2 million in 2023, then dropped by 0.08% to -$73.3 million in 2024, then soared by 74.55% to -$18.6 million in 2025, then plunged by 187.14% to -$53.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$53.5 million (Q1 2026), -$18.6 million (Q4 2025), and -$79.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | -53.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | -18.64 Mn |
| Sep 30, 2025 | -79.42 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -73.26 Mn |
| Sep 30, 2024 | -44.38 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | -73.21 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | 8.21 Mn |
| Sep 30, 2021 | -36.53 Mn |
| Jun 30, 2021 | 399.47 Mn |